Multiple Myeloma — Fourth Annual National General Medical Oncology Summit
Clinical investigators discuss available data guiding the management of multiple myeloma. CME information and select publications here.
--------
50:41
Multiple Myeloma — An Interview with Dr Rafael Fonseca on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting
Dr Rafael Fonseca from Mayo Clinic in Phoenix, Arizona, discusses datasets from the 2024 ASH meeting on the management of newly diagnosed and relapsed/refractory multiple myeloma. CME information and select publications here.
--------
50:50
Chronic Lymphocytic Leukemia — An Interview with Dr Lindsey Roeker on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting
Dr Lindsey Roeker from Mayo Clinic in Rochester, Minnesota, discusses recent updates on available and novel treatment strategies for chronic lymphocytic leukemia. CME information and select publications here.
--------
48:22
Relapsed/Refractory Follicular Lymphoma Part 3 — A Roundtable Discussion on the Selection and Sequencing of Other Novel Therapies
Dr Carla Casulo from Wilmot Cancer Institute in Rochester, New York, Dr Matthew Matasar from Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Laurie H Sehn from BC Cancer Centre for Lymphoid Cancer in Vancouver discuss recent updates on available and novel treatment strategies for relapsed/refractory follicular lymphoma. CME information and select publications here.
--------
42:34
Non-Hodgkin Lymphoma — An Interview with Dr Jennifer Crombie on the Use of Bispecific Antibodies
Dr Jennifer Crombie from the Dana-Farber Cancer Institute in Boston, Massachusetts, reviews available and investigational CD20 x CD3 targeted bispecific antibodies for the treatment of follicular and diffuse large B-cell lymphomas. CME information and select publications here.
Featuring one-on-one interviews conducted by Dr Neil Love, this series provides medical oncologists with access to an array of important perspectives and information on relevant advances in the treatment of hematologic cancer to facilitate optimal patient care.
Colombia